Pfizer Extends RNA Drug Deal

Jan 5, 2011, 01:00 AM by Michael Croft

Bloomberg | Pfizer is expanding Wyeth's 2009 RNA-focused partnershp with Santaris Pharma in a deal that could be worth more than $600 million.

January 5, 2010 | Pfizer is expanding Wyeth's 2009 partnershp with Santaris Pharma in a deal that could be worth more than $600 million. Pfizer will pay Santaris $14 million for up to 10 drug candidates designed to target RNA. Milestone payments and royalties would follow any approved drugs. Bloomberg